Long Term Follow-Up of Participants Exposed to GSK3377794 (NYESO- 1c259 T), a Genetically Engineered NY-ESO-1 Specific T Cell Receptor
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
GlaxoSmithKline
Start Date
June 29, 2020
End Date
May 31, 2025
Administered By
Duke Cancer Institute
Awarded By
GlaxoSmithKline
Start Date
June 29, 2020
End Date
May 31, 2025